How Retatrutide Titration Works
Retatrutide is a once-weekly injectable triple agonist (GLP-1, GIP, and glucagon receptors) developed by Eli Lilly. The standard titration protocol increases the dose every 4 weeks to minimize gastrointestinal side effects while building toward the therapeutic range.
Standard Titration Schedule
Dosing begins at 2 mg for 4 weeks before increasing to 4 mg, 8 mg, and eventually a 12 mg maintenance dose. This helps the body adapt to the medication gradually.
Why Gradual Titration Matters
Ramping up slowly mitigates severe gastrointestinal side effects like nausea and vomiting. Clinical trial protocols, such as TRIUMPH, carefully scaled the dosage up every four weeks to establish a baseline for tolerability.
TRIUMPH-4 Trial Results
The TRIUMPH-4 and TRIUMPH-1 studies demonstrated that participants taking 12mg of retatrutide experienced an average of 28.7% weight loss at 48 weeks, making it highly effective.
Conservative vs. Standard Titration
For individuals who are highly sensitive to side effects (e.g., severe nausea), a conservative titration profile (1mg → 2mg → 4mg → 8mg → 12mg) may be advised by their healthcare providers. This tool supports custom step calculations.
Frequently Asked Questions
What is the starting dose of retatrutide?
The standard starting dose is 2 mg once weekly, administered subcutaneously.
How long does retatrutide titration take?
The standard protocol reaches the maximum dose of 12 mg in 13 weeks (4 dose levels × 4 weeks each, starting at 2mg).
What side effects should I expect during titration?
The most common side effects are gastrointestinal: nausea (43%), diarrhea (21%), vomiting (21%), and decreased appetite. A unique side effect of retatrutide is dysesthesia (tingling/numbness).
Can I stay on a lower dose if it's working?
Yes. Clinical trials studied 4mg, 8mg, and 12mg as maintenance doses. Many patients achieve satisfactory weight loss at 8mg.
When will retatrutide be available?
Eli Lilly is expected to submit an NDA in late 2026, with a potential PDUFA date in October 2027.
Disclaimer:
This tool is for educational and informational purposes only. It does not constitute medical advice. Retatrutide is an investigational medication not yet approved by the FDA or EMA. Always consult your healthcare provider before starting or modifying any medication. Dosing projections are based on population averages from clinical trials — individual results vary significantly.